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Lynch CJ. Considerations for best practices in studies of fiber or
other dietary components and the intestinal microbiome. Am J Physiol
Endocrinol Metab 315: E1087–E1097, 2018. First published August
21, 2018; doi:10.1152/ajpendo.00058.2018.—A 2-day workshop or-
ganized by the National Institutes of Health and U.S. Department of
Agriculture included 16 presentations focused on the role of diet in
alterations of the gastrointestinal microbiome, primarily that of the
colon. Although thousands of research projects have been funded by
U.S. federal agencies to study the intestinal microbiome of humans
and a variety of animal models, only a minority addresses dietary
effects, and a small subset is described in sufficient detail to allow
reproduction of a study. Whereas there are standards being developed
for many aspects of microbiome studies, such as sample collection,
nucleic acid extraction, data handling, etc., none has been proposed
for the dietary component; thus this workshop focused on the latter
specific point. It is important to foster rigor in design and reproduc-
ibility of published studies to maintain high quality and enable designs
that can be compared in systematic reviews. Speakers addressed the
influence of the structure of the fermentable carbohydrate on the
microbiota and the variables to consider in design of studies using
animals, in vitro models, and human subjects. For all types of studies,
strengths and weaknesses of various designs were highlighted, and for
human studies, comparisons between controlled feeding and observa-
tional designs were discussed. Because of the lack of published,
best-diet formulations for specific research questions, the main rec-
ommendation is to describe dietary ingredients and treatments in as
much detail as possible to allow reproduction by other scientists.
dietary fiber; gastrointestinal; in vitro fermentation; microbiota; nu-
trition
INTRODUCTION
“Life would not long remain possible in the absence of
microbes.”
–Louis Pasteur
Enormous progress in defining the human intestinal micro-
biome has been made over the last decade, in large part,
beginning with the launch of the National Institutes of Health
(NIH) Human Microbiome Project that has stimulated research
support from other funders. Many papers and workshops have
addressed a variety of best practices needed to improve anal-
yses that are part of understanding the complex ecosystem in
the gut, such as sampling, nucleic acid extraction, methods to
identify microbes and their metabolites, and data reduction and
analysis; these were specifically excluded from discussion at
this workshop. However, there have been few attempts to
standardize the dietary aspects of studies on the intestinal
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microbiome, whether in vitro, in animal models, or in humans.
Most published studies report only minimal information on
dietary components, even though there is substantial evidence
that diet is a primary modulator of microbial composition. A
workshop organized by program staff of the NIH and the U.S.
Department of Agriculture, Agricultural Research Service,
brought together 16 speakers focused on dietary aspects of
microbiome studies. The purpose of the workshop was to
improve rigor and reproducibility in research on the colonic
microbiome and to identify important dietary information that
should be reported and parameters to consider in design of
research studies, particularly for clinical studies on diet and the
intestinal microbiota. The workshop was held on the NIH
campus on June 13 and 14, 2017, and was attended by ~100
people on site and 100 via webinar. Extensive time was built
into the workshop schedule to allow discussion of topics on
which there were no obvious solutions.
WORKSHOP SUMMARY
Focus on dietary fiber. The workshop’s opening session
focused on the structure of dietary fiber and other indigestible
carbohydrates and their relevance to feeding the microbes in
the colon. Estimates of macronutrients that are unabsorbed in
the small bowel include 2–10 g/day of sugars, 3–9 g/day of
protein, 8–40 g/day of resistant starch, 2–10 g/day of oligo-
saccharides, and 10–20 g/day of dietary fiber; the latter three
food components are the dominant nutrient sources for the
colonic microbiota, and all analyze as dietary fiber but are
usually reported as distinct entities. Other potential nutrient
sources for gut microbes include endogenous secretions
from the gastrointestinal (GI) tract, such as proteins, en-
zymes, and bile acids (estimated at 4 – 6 g/day), mucin (2–3
g/day), and sloughed epithelial cells. The term “dietary
fiber” has had multiple definitions over the last 60 yr, which
has contributed to a lack of consistency in reporting. Even
today, the Codex Alimentarius definition of dietary fiber
includes carbohydrate polymers with 10 or more monomeric
units that occur naturally in foods or are synthesized but are
not hydrolyzed by the endogenous enzymes in the small
intestine of humans and is accepted by 187 member nations.
However, this leaves to national authorities the option of
including fibers with degrees of polymerization between
three and nine; carbohydrates with degrees of polymeriza-
tion 10 are universally acknowledged as meeting the
definition, but the assays to analyze them vary. For purposes
of this discussion, the broader definition of dietary fiber is used.
Although that includes oligosaccharides and resistant starch
forms, those are identified separately, because they are almost
always described as such in research studies.
The three-dimensional structures of dietary fibers are not
uniform and have not been completely described. This is
important for microbial access to these polymers and their
susceptibility to fermentation. Despite many claims in the
literature that several forms of fiber are not fermented, only
lignin, isolated microcrystalline cellulose, and certain resistant
maltodextrins are truly unfermentable by gut microbes. Within
a plant, different types of tissues, such as vascular, paren-
chyma, mesophyll, and epidermis, contain different structural
forms and types of dietary fiber that are connected to variable
amounts of proteins with different constituent amino acids.
These tissues are composed of different cell types, cell-wall
thicknesses, amounts of lignin, and propensity toward being
fermentable. The types of bonds and covalent or noncovalent
linkages between fiber types and proteins are also remarkably
variable. Whole grain foods contain resistant starch as well as
fiber, but the physical process of milling grains has major
effects on chemical composition and subsequent use.
There are at least four types of resistant starch differing in
chemical structure, but all escape digestion in the upper GI
tract and serve as nutrient sources for bacteria in the colon.
Physical factors of dietary fiber that are relevant to bacterial
fermentation include viscosity, gel-forming capacity, and wa-
ter-holding ability. The terms “soluble” and “insoluble” fiber
are useful from an analytical perspective; Koropatkin et al. (20)
showed that soluble fiber is usually fermented in the prox-
imal colon, and insoluble fiber is fermented more distally
but usually not completely. Classifications based on the
physicochemical properties of the fibers, including solubil-
ity, viscosity, and fermentability, which are related to the
clinical outcomes of fiber consumption, such as laxation and
cholesterol-lowering effects, are also relevant when consid-
ering diet-microbiota interactions, especially in human sub-
jects. The complexity of secondary and tertiary structures of
dietary fiber types cannot be overemphasized; secondary
structure refers to the linear chains of carbohydrate moi-
eties, whereas tertiary structure refers to the three-dimen-
sional arrangement that may differ in which bacterial en-
zymes digest it. Fiber is the most chemically complex of any
food constituent important in nutrition, which likely explains
issues inherent to its definition and analysis. However, the
knowledge of the amount and chemical type of fiber is insuf-
ficient due to the complexity of the diet matrix in which it is
presented if we are to understand how the intestinal micro-
biome ferments various forms of dietary fiber.
There are hundreds, or perhaps thousands, of discrete fiber
structures that align with bacterial digestive abilities. Discrete
structures may provide competitive niches for different bacte-
rial strains. For example, only some Bacteroides ferment com-
plex arabinoxylans, whereas most do not. Prevotella have not
been proven to ferment these complex arabinoxylans (9a). In
addition to the naturally occurring nonstarch polysaccharides,
nondigestible oligosaccharides, and resistant starch, novel car-
bohydrate compounds have been synthesized, such as polydex-
trose and mixed-linked -glucans, which share lack of digest-
ibility by mammalian enzymes but are partially degraded by
gut bacteria. The potential exists to match fiber types/structures
with bacterial strains to favor growth in the colonic environ-
ment. It may be possible to promote or suppress specific
bacteria using custom-blended fiber formulations. Prebiotics
are types of dietary fiber or resistant starch that stimulate the
growth of beneficial bacterial species, such as lactobacilli or
bifidobacteria.
Investigation of the genes for carbohydrate processing in
Bacteroides thetaiotaomicron and Bacteroides ovatus reveals
almost 2,000 genes that code for ~650 enzymes, far more than
exist in mammalian systems (24), allowing those two species
to degrade nearly all common glycans derived from diet or host
secretions. Use of a synthetic gut microbiota in gnotobiotic
mice, comprised of 14 commensal bacterial species, demon-
strated that when fermentable fiber is not included in the diet,
colonic mucin is preferentially used (12). Within 2 weeks,
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significant declines in B. ovatus and Eubacterium rectale are
noted, with large expansions of Akkermansia muciniphila and
Bacteroides caccae, which preferentially degrade mucin, asso-
ciated with thinning of the protective layer in some but not all
studies, exposing the colonic epithelial layer to the opportu-
nistic pathogen, Citrobacter rodentium, and subsequent mor-
bidity and mortality. Some of the relevant questions related to
these observations were the following: 1) whether gnotobiotic
animals with defined microbiota are valid models of animals
with natural microbiota; 2) whether humanized mice were
more realistic; 3) whether those with conventional microbiota
exhibit colony-to-colony variation; 4) whether an optimal diet
for animals in such studies is a natural diet or a fiber-free base
to which defined fibers are added and how such diets should be
processed and cooked to mimic the human food supply; and 5)
the causes of variation in both animal and human microbiota,
including both diet and host factors. Most of the answers
depend, in part, on the experimental question being asked, but
currently, there are no clear answers to any of these issues.
Thus a best practice is for investigators to provide as much
detail as possible about feeding and housing conditions of test
subjects, even if only as online supplemental material for their
papers.
Other dietary factors. As noted above, macronutrients are
not completely assimilated in the small intestine, so some
provide fermentable substrate in the colon. In addition to
polysaccharides, non-nutrient food constituents can modulate
the composition and activity of the colonic microbiome.
Among the more prominent food-derived factors are the poly-
phenols. Numerous polyphenols are obtained from coffee, tea,
wine, fruits, and vegetables; berries are especially rich sources
and can contain various classes of polyphenols, such as tan-
nins, flavonoids, anthocyanins, and proanthocyanins. For ex-
ample, a polyphenol-rich extract of cranberry added to a
high-fat, high-sugar diet fed to mice led to modified gut
microbiota, reduced intestinal inflammation, insulin resistance,
and obesity compared with mice that only received the high-
fat, high-sucrose diet (1). Other modulators of the gut micro-
biota are proteins and omega-3 polyunsaturated fatty acids;
these dietary components also improve glucose tolerance, in-
flammation, and dyslipidemia in mice (10). Most, if not all,
rodent studies using purified diets have casein as the sole
dietary protein source, which is practical but not at all relevant
to the human diet that contains a mix of proteins. Any purified
protein or mixture of them can be used in animal diets, but the
ideal depends on the question being asked and is affected by
availability, purity, and cost. In addition to digestible and
fermentable food components, several food additives have
been studied in mouse models to examine whether they alter
the microbiota. Part of the rationale for these studies is the
large geographic variation in prevalence of inflammatory
bowel disease (IBD), which may result from changes in the
microbiome due to variable exposure to environmental factors,
including diet. Whereas many nondietary, hygiene-related fac-
tors vary geographically, some food additives are widely used
and could modify viability of gut bacteria. For example, the
emulsifiers Polysorbate 80 and carboxymethylcellulose, which
are detergent-like molecules that stabilize mixtures of immis-
cible liquids, alter the mouse intestinal microbiota in a detri-
mental way, promoting colonic inflammation and metabolic
syndrome, although the extent to which the experimental
administration of these compounds in feed or drinking water
mimics human exposure to these compounds is unclear (6).
These compounds also increase lipopolysaccharide and flagel-
lin concentrations in feces from mice while thinning the co-
lonic mucin layer, leading to colitis in genetically susceptible
animals and to low-grade intestinal inflammation in unim-
paired hosts. These changes were associated with increased
adiposity, with those differences eliminated in germ-free mice.
Such detrimental effects were observed even at doses thought
to mimic reasonably the overall consumption of emulsifiers by
people who eat many processed foods. The two emulsifiers
were studied for effects on the human microbiome in the
mucosal simulator of the human intestinal microbial ecosys-
tem, and the new steady-state microbiotas were transferred to
germ-free mice. Recipients of the emulsifier-treated in vitro
microbiotas gained more weight, were glucose intolerant, and
had significantly shorter colons with thinner mucin layers,
allowing bacteria close access to the epithelial lining (9). The
latter observation also was seen in humans with type 2 diabe-
tes; distance of bacteria from the colonic epithelial layer
significantly correlated with measures of glucose intolerance
(8). By highlighting the importance of diet/microbiota interac-
tions in health and disease, semi-purified diets containing fat at
the same concentration as in chow, but devoid of fermentable
fiber, led to higher weight gain and reduced large bowel mass
(7). Conversely, the supplementation of a high-fat diet with the
fermentable fiber inulin but not the poorly fermented fiber
cellulose resulted in a microbiota-dependent fortification of the
mucosa that prevented microbiota encroachment and protected
against high-fat, diet-induced metabolic syndrome. Hence, not
only higher fat but also absence of fermentable fiber can render
a diet obesogenic. However, whereas the enrichment of a
high-fat diet with inulin prevented high-fat, diet-induced gut
atrophy and greatly reduced metabolic syndrome, mice con-
suming inulin-enriched purified diets of low- or high-fat con-
tent developed extremely severe colitis upon exposure to the
chemical dextran sulfate sodium (27). Thus whereas strategies
to enrich foods with fermentable fiber may hold long-term
potential to induce a more beneficial microbiota composition,
at present, our relatively poor understanding of how various
dietary components impact both the microbiota and host in a
range of contexts currently precludes certainty for the goal of
promoting gut health.
Focus on rodent models. A vast array of experimental diets
is fed to a large range of animal models. Most common diets
are closed formulations (the percent of each ingredient varies
to provide minimal variation in nutrient content) that vary in
composition from batch to batch while meeting macronutrient
requirements and are usually described as “chow” diets or
natural ingredient diets. Another choice is open formula diets,
such NIH-31, which do not vary in ingredient composition
from batch to batch but may have slight variations in nutrient
content. Open formula diets can range from those that are
composed primarily of grains and other so-called “natural”
ingredients to semi-purified diets, such as the American Insti-
tute of Nutrition (AIN)-93 formulations that are made from
clearly defined ingredients, such as casein, corn starch, and
soybean oil. Although AIN-93 is considered the gold standard
in nutritional studies with rodent models, it was developed to
prevent nutrient deficiencies, but the main criterion was max-
imum growth. That diet contains no fermentable dietary fiber
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or other macronutrient that is intended to resist digestion in the
small intestine. For this reason, the concept of microbiota-
accessible carbohydrate (MAC) is important to define those
foods or nutrients that fuel the gut microbiome (38).
Because of reduced diversity in the gut microbiota among
Western populations compared with those eating more tradi-
tional diets, an animal model was developed to understand this
potentially important observation. Humanized mice were fed a
high- or low-MAC diet. Those on the low-MAC diet were
maintained for four generations. Changes in the gut microbiota
were reversible during the first generation, but feeding the
low-MAC diet resulted in increasing loss of diversity that was
not reversed by switching the animals back to the high-MAC
diet at the fourth generation, although a fecal transplant, along
with the high-MAC diet, was able to restore diversity (39).
The question of whether standard rodent chow is an appro-
priate control diet in gut microbiome studies was considered.
Chow or standard chow refers to a variety of commercially
available closed or open formula animal diets obtained by an
animal facility in bulk to feed its animals. These diets are
usually economically priced, low in fat (5–10% of energy), and
optimized for protein and other nutrients for healthy growth of
each species (rodent chow, monkey chow, etc.). It is tempting
to use chow, because it is inexpensive and generally results in
excellent metabolic health of most laboratory animals, includ-
ing moderate weight gain and low concentrations of plasma
lipids, glucose, and insulin. Chow feeding also results in the
highest cecal and fecal weights, along with the highest con-
centrations of short-chain fatty acids (SCFAs). Data were
presented that recovery of some bacterial orders was uniquely
influenced by chow diets, especially Anaeroplasmatales and
Verrucomicrobiales. Since there are likely differences in the
gut microbiota with weight status in humans and rodents, clear
answers are not yet available on whether weight gain is an
independent variable for changes in bacterial content or func-
tion. Likewise, the effects on the microbiota of diet sterilization
(animal diets are not sterile) by autoclaving or irradiation that
affects the tertiary structure of starch and protein are not
known. Furthermore, whereas we know that there are different
growth patterns of some inbred strains of mice and rats, we do
not have data on whether strains differ in their microbiota
composition or metabolic patterns. Finally, we do not have
adequate data on organisms other than bacteria, such as ar-
chaea, fungi, viruses, parasites, and bacteriophage or many of
their functional capacities.
Nonrodent models. The use of nonrodent models for GI
microbiome research was considered. Because of the large
cecum in all rodent species and their coprophagy, there are
likely fundamental differences in microbial activity and fiber
requirements that differ from humans. Larger animals, such as
pigs and dogs, also have the same key advantages of more
commonly used rodents—short generation time, access to
intestinal contents and tissues, relevant disease models, and
control of experimental variables—but have GI physiology
and anatomy, as well as omnivorous eating patterns closer to
that of humans. In addition, these larger animals are, like
humans, susceptible to diarrhea, which is rare in rodents.
Primary advantages of the swine model include similar devel-
opmental stages to human infants, large litters, short generation
times, and germ-free possibilities. The size of pigs allows for
easier surgery if needed and many sampling options, including
cannulation, at different sites on the GI tract. Additionally,
some strains of pigs, such as the Ossabaw mini-pigs, naturally
become obese and display the diagnostic criteria for metabolic
syndrome. Limitations to the use of swine are their large size
and expense and the relative paucity of laboratory facilities for
housing them.
The dog is one of the most commonly used nonrodent
models in biomedical research, particularly in pharmacological
studies. Dogs become obese and display associated patholo-
gies, as well as IBD, cancers, and other chronic conditions.
Their genome is well characterized, and the diversity among
breeds can be a strength. Canine IBD shares many similarities
to the human disease with decreased alpha-diversity of the
microbiome, decreased Faecalibacteria, and increased Gamma-
proteobacteria and Escherichia coli (41). The dog’s micro-
biome displays similarity of microbial taxa, functional capac-
ity, and activity to that of humans (40) with similar responses
to inclusion of dietary fibers or prebiotics. Potential drawbacks
to use of the canine model are their size, expense, expertise
needed in handling, and animal welfare concerns.
Focus on in vitro systems for the study of the gut microbial
ecosystem. Several systems are available, including simple
batch fermentation, single-stage bioreactors, multistage biore-
actors in which each stage models a different compartment of
the GI tract (e.g., simulator of the human intestinal microbial
ecosystem), and miniaturized systems, such as minibioreactor
arrays or HuMIX (a microfluidics-based, human microbial
coculture model system), which allow volumes of 15 ml or 400
l, respectively. Depending on the question asked, one may
select inocula of bacterial monocultures, defined mixed popu-
lations (which are usually limited in number of species but may
have 80), or whole fecal microbiota. Several strengths of in
vitro models exist, including minimal ethical constraints, ex-
perimental reproducibility, sampling accessibility, absence of
host factors affecting bacterial viability (which also may be a
limitation), and lack of absorption of metabolites, making them
easier to measure. Key challenges of these models include the
choice of the best inoculum; nature of the nutrient supply;
emulation of the mucosal, as well as luminal, environments;
lack of host components, including immunoglobulins; and
need for high water content to allow flow through the system.
A number of variables come into play in trying to emulate
natural conditions, including temperature, which is known and
easy to control; flow rate and pH, which both vary but gener-
ally require an average of known values; oxygen tension,
which is very low in a healthy colonic lumen but may be fairly
high near the mucosal surface and is usually controlled by the
displacement of oxygen with nitrogen; water content; and
food/nutrients, which are very complicated to mimic natural
conditions.
The issue of inoculum is very important since feces are
generally used to seed such systems, but such samples may be
only representative of the distal colon. Other regions of the GI
tract can be sampled by colonoscopy or endoscopy; patients
with stomas, such as ileostomies, can be sampled, but there is
always the concern over whether these are representative of the
healthy population, and the issue of oxygen tension under these
conditions is also a factor for consideration. Nevertheless, it
appears that bioreactor contents may be more representative of
the resident colonic bacterial community than that of feces
(26). Because gut microbiota differ from individual to individ-
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ual, it is difficult to ensure experimental relevance if a small
number of donors are used. Some studies have suggested that
fecal inocula can be pooled to create an average ecosystem, but
this is controversial, with some data suggesting that one do-
nor’s microbiome outcompetes another’s. Relevant to this
point is the estimated diversity of the colonic microbiota.
Whereas it is often stated that 1,000 species exist within each
person, this number has been challenged, and there may be
only 100–200 species per person (2). Just as the total number
of colonic bacteria was cited in the past as being 10 times that
of human cells, a more accurate estimate is likely equal in
number (33). Important to studying this complex ecosystem is
the low abundance of some strains, particularly those associ-
ated with the mucosa that may not be well represented in fecal
samples. Additional data describing the full phenotype of the
donor will also be helpful in establishing factors that matter for
comparing data from different donors, such as dietary habits,
health status, and drug or dietary supplement exposure.
The feeding of in vitro systems is virtually always designed
by microbiologists and not nutritionists. To represent nutrient
availability best in the colon, bioreactors need a medium that
represents chyme from the terminal ileum. Most media do not
accurately reproduce what is in the digesta. Furthermore, some
microbes are adapted to niches in the colon, such as association
with the mucin layer (25). Mucin can be added to the system to
enhance growth of mucin-associated species, such as A. muci-
niphila. Some believe it is important to allow development of
a steady state, often after a period of weeks, but others use
models, such as the TNO intestinal model 2, that use dialysis
to maintain physiological concentrations of metabolites, such
as SCFA, eliminating the need for a steady state and thus
designed for shorter, often 3-day, running cycles (43).
When asked “How many investigators in the audience of the
workshop report that their fecal donors follow a typical diet
and have not taken antibiotics for some period of time?” most
attendees responded that was their practice. This demonstrated
the general lack of reporting detail for this parameter, given the
large number of dietary compounds that have the potential to
affect growth of the GI microbiota. The provision of a dietary
and medical history of fecal donors should be standard prac-
tice, perhaps as supplemental online material. There is substan-
tial interlaboratory variability in results of fecal fermentation
studies when well-characterized, single types of resistant starch
are added. Much of this variation can be attributed to the diet
and consequently, different microbiota of fecal donors. Bu-
tyrate, produced in vitro, correlates strongly with several nu-
trients available from plant foods, including dietary fiber, plant
protein, and several micronutrients. Not surprisingly, those
correlations can be observed with fermentation by specific
bacteria, such as Faecalibacterium prausnitzii. However, it is
rare to report diet of fecal donors other than that they followed
an unspecified “average” diet, even though there is strong
evidence pointing to this factor having major influence on the
results (48). In addition, the occurrence of obesity in donors
appears to be a substantial factor in the ability of fecal samples
to produce butyrate following in vitro incubation (47).
Focus on human studies of the colonic microbiome. Numer-
ous challenges in characterizing the effects of diet on the
human gut microbiome were highlighted, including poor ad-
herence to specific diets, relatively inaccurate characterization
of dietary intake and composition, the reciprocal nature of
dietary changes when isocaloric conditions are maintained,
high costs, and other logistical challenges in completing either
controlled feeding or large cohort studies. In addition, human
observational studies generally point out associations so that a
combination of reliance on model systems along with con-
trolled feeding studies of volunteers is needed. Therefore,
reasoned use of a combination of human and animal model
studies may prove more informative than either approach
alone.
In addition to the microbial diversity among humans noted
above, there are seasonally stable and seasonally labile species
identifiable in feces from the Hadza of Tanzania, the last true
hunter-gatherers in East Africa (37). A potential result of the
lower diversity in Western populations is reduced metabolic
output from the gut microbiota; this has been shown for
SCFAs, but there may be other biological mediators absorbed
from the colon that interact with receptors on cells beyond the
intestine. Better tools are needed to study how individual
bacterial strains establish a geographic niche in the gut. One
successful approach is the use of a novel phage promoter and
fluorescent protein expression in various species of Bacte-
roides that allow quantitative identification and differentiation
of strains within the gut, down to the level of colonic crypt
occupancy (42). Although fermentable substrates, such as in-
ulin, can drive increases in specific bacterial species, the ability
of a single strain to colonize a pre-existing microbiota is
variable. An example of the ability of ingested bacteria to
transfer genes to microbiota in the human gut is for digestion
of sulfated polysaccharides, specifically the porphyrans and
agar found in seaweed (18). This phenomenon is exemplified
by differences in the fermentability of these substrates by
Japanese versus North Americans. Japanese eat ~14 g/day of
seaweed, and their microbiota can ferment these polysaccha-
rides, whereas North Americans, who generally do not con-
sume seaweed, cannot ferment these substrates. These obser-
vations suggest that the ability to use polysaccharides from
other food sources can be engineered into the human micro-
biome.
Whereas changes in gut bacteria have been reported among
subjects who are at healthy weight, obese, or following bari-
atric surgery, the observed modifications are not always repro-
ducible. Animal models and controlled feeding of humans can
be used to address these phenomena to provide clear answers
in adequately powered studies. Germ-free mice are resistant to
obesogenic diets, and hepatic gene expression is markedly
different in germ-free versus conventional mice (21). Among
these differences are genes responsible for circadian rhythm
signaling. The mouse microbiome exhibits diurnal oscillations
that are influenced by high- and low-fat diet; this observation
is consistent with diurnal fluctuations in cecal concentrations of
metabolites, such as butyrate and hydrogen sulfate. These
metabolites, in turn, alter hepatocyte circadian clock function
and responsiveness within areas of the central nervous system.
Timed administration of butyrate injected intraperitoneally can
correct high-fat, diet-induced hepatic circadian dysfunction and
obesity, suggesting that a modulating role of the gut microbiota
may be sample time dependent. The conclusion from these ob-
servations is that the low-fat diet results in normal microbiome
signals leading to both normal circadian functions and body
weight, whereas the high-fat diet results in aberrant microbial
oscillations and signals that lead to circadian disruption and
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obesity (21). Germ-free animals lack microbial signals no matter
which diet they are fed but still have circadian disruption and fail
to become obese on a high-fat diet. All of these data suggest that
the recording of the time of fecal collection in both animals or
humans is needed.
A cross-sectional study of vegans and omnivores assessed
diet with repeated 24-h recalls before sampling of plasma,
urine, and stool for metabolomics and microbiota (46). Con-
trary to what most would have expected, higher consumption
of fermentable substrates by vegans was not accompanied by
increased concentrations of fecal SCFA, which was confirmed
in a 10-day controlled feeding study. Of course, fecal concen-
trations of SCFA may not reflect in vivo exposure well since
95% or more are absorbed before elimination of stool. In a
study of 98 subjects, fecal microbiota were clustered into
enterotypes distinguished primarily by Bacteroides and Pre-
votella (45). These enterotypes were associated with long-term
diet, particularly protein and animal fat (Bacteroides) versus
carbohydrates (Prevotella). The vegans and omnivores had
considerably different plasma and urinary metabolomes, but
there were not huge differences in their microbiota, including
measures of diversity. Intersubject differences in humans ap-
pear more important than many other factors, and this remains
unexplained. A subset of subjects fed controlled diets that
varied in fat and fiber maintained enterotypes but exhibited
significant microbiome changes. Multiple studies implicate
factors in both the diet and microbiome in IBD. Defined
formula diets for treatment of Crohn’s disease are most effec-
tive when they completely replace the normal diet of patients
(22). Numerous metabolic changes result from alterations in
the gut microbiota, not just from fermentation of indigestible
carbohydrates but also from metabolism of minor amounts of
other macronutrients, micronutrients such as choline, and con-
version of bile acids from primary to secondary metabolites. In
addition, many of the microbial metabolites are absorbed from
the colon and circulate in the plasma, affecting target tissues in
extraintestinal organs. This observation suggests the novel
therapeutic modalities of either engineering the microbiota or
feeding defined diets that alters production of small metabolites
in the colon.
Presently, there is no biomarker available that reflects di-
etary fiber intake, so researchers rely on dietary histories that
are often unreliable. The current Dietary Reference Intake
recommendations for fiber are based on prevention of coronary
heart disease from three observational cohort studies and are
set at 14 g · 1,000 kcal1 · day1, which translates to 38 g/day
for young men and 25 g/day for young women, far more than
current consumption in most Western countries. Studies aimed
at increasing dietary fiber intake to 35 g/day have failed to
prevent recurrence of adenomatous polyps (34), but experi-
mental studies have shown that there is a threshold level for
fermentation products derived from fiber, specifically butyrate
that suppresses epithelial cell proliferation and tumorigenesis.
The fiber/resistant starch concentration in the traditional Afri-
can diet is 50 g/day and is associated with low colon cancer
risk (29). Although the Polyp Prevention Study failed to show
any difference in recurrence of adenomas with dietary inter-
vention up to 8 yr, subgroup analysis showed a significant
reduction in recurrence of advanced (1 cm, 25% villous, or
high-grade dysplasia) polyps in those consuming the highest
quartile of high-fiber beans (30). With this background, a study
was planned to compare a typical American diet with a tradi-
tional African diet in both native Africans and African-Amer-
icans for effects on fecal bile acids, SCFA, and biomarkers of
colonic mucosal proliferation (29). The African diet provided
55 g/day fiber and 41 g/day fat, whereas the African-American
diet contained 7 g/day fiber and 145 g/day fat. There is a
10-fold higher risk of colon cancer in African-Americans
than in rural South Africans. The switching of diets resulted in
marked reciprocal changes in SCFA, secondary bile acid for-
mation, and markers of epithelial cell proliferation. In addition,
the dietary switch resulted in noticeable shifts in the compo-
sition of the microbiota, with Prevotella dominant while fol-
lowing the African diet and Bacteroides dominating while
following the African-American diet (30). Since diet can in-
fluence the relative concentrations of certain bacteria in the
colon, it is relevant that a systematic review of both humans
and animal models evaluating the microbiota and colorectal
cancer concluded that the presence of the disease is associated
with consistent increases of species members from Fusobac-
terium, Alistipes, Porphyromonadaceae, Coriobacteridae,
Staphylococcaceae, Akkermansia, and Methanobacteriales,
whereas others that were consistently decreased were Bifido-
bacterium, Lactobacillus, Ruminococcus, Faecalibacterium,
Roseburia, and Treponema (3). In addition, bacterial metabo-
lites of amino acids were increased, and butyrate was de-
creased in association with colorectal cancer in both humans
and animals. Although more studies are needed, current data
collectively suggest that at least 50 g/day of fermentable
substrate is needed to reduce risk factors for colon cancer.
A number of issues are routinely ignored in studies of the
human intestinal microbiota. The digestive tract is an open
system, so dietary effects should never be discounted. Samples
from the colon are essentially snapshots that do not distinguish
between permanent and transient resident strains. Since it is
generally assumed that each individual has his/her own micro-
biota, a large number of samples are likely needed to reach
valid conclusions, and the effect of any dietary intervention
will depend on the individual’s baseline microbiota. Whereas
diet explains ~60% of the variation in the gut microbiome of
mice due to standardized feed and environmental conditions, it
only explains ~10% of the variation in humans (31). Those
differences may result from genetic differences, level of con-
trol over diet and environment, amount of fiber used, sample
collection methods, and other variables. This observation raises
the issue of whether researchers have relied too heavily on
rodent models in predicting efficacy in humans. Although it is
logical to focus on dietary fiber and other sources of ferment-
able carbohydrates, ~10% of ingested protein reaches the
colon, and many bacterial metabolites of its fermentation, such
as sulfides, phenols, polyamines, and ammonia, are harmful to
the mucosal tissue. Diets high in protein or fat are necessarily
low in both digestible and nondigestible carbohydrates, making
it almost impossible to attribute causality to an individual
macronutrient. An analysis of stool microbiota in monozygotic
twins showed that intakes of energy, unsaturated fatty acid
classes, and soluble fiber affected microbiota composition,
particularly for Bacteroides spp. and Bifidobacterium spp., but
body mass index was not a factor (36). The effect of diet is not
the additive effect of individual nutrients, but diet needs to be
considered as a totality. An unresolved question is whether a
group of human subjects fed the same foods for perhaps 1 week
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would show reductions in the marked interindividual variabil-
ity alluded to above. A related question is whether dosage of
dietary fiber should be provided in equal amounts daily, based
on energy intake, metabolic body weight, or some other fac-
tors. There are currently no data to address these issues.
Although such a dietary approach would be of limited gener-
alizability to a diverse population, it would answer an impor-
tant question.
Diet is a highly complex exposure, providing thousands of
compounds in complex mixtures, and food structure, especially
of plants, is rarely captured but may be important in determin-
ing what reaches the colon. Researchers often consider dietary
intake in different ways, such as by individual foods or classes
of foods, individual compounds, or dietary patterns. Controlled
feeding studies use diets prepared to exact specifications and
are the strongest in measuring a biologic effect of a dietary
manipulation, but these studies are not designed to evaluate
application of that dietary intervention under real-world con-
ditions and are the most expensive to conduct. These studies
can be conducted in parallel arms or with a crossover design;
under the latter, all subjects receive all interventions, and each
person serves as his/her own control. In crossover designs, it is
essential that the washout period between treatments is long
enough to be certain that the gut microbiota returned to its
initial composition, but that time period has yet to be estab-
lished, although it is likely at least a couple of weeks, based on
typical GI transit times. These conditions allow tight dietary
control, potential to test dose-response relationships, and mon-
itoring of intermediate biomarkers, but limitations include a
relatively short-term intervention, high expense, and inability
to evaluate hard disease end points. One example is a study of
feeding cruciferous vegetables containing glucosinolates and
dietary fiber to alter the gut microbiome that used a low-fiber,
low-phytochemical basal diet for comparison with the crucif-
erous-rich diet that provided high amounts of both compounds
with each diet fed for 2-week periods (23). Each diet resulted
in different fecal bacterial communities thought to influence
metabolism of these bioactive food components. Although
many individual nutrients may affect the intestinal microbiota,
use of dietary patterns addresses some of the limitations of the
single nutrient approach, including the high correlation among
intakes, multidimensional aspects of foods, and inclusion of
nutrients and non-nutrients. Short-term feeding of animal- or
plant-based diets substantially alters the fecal microbiota but
does not overcome large interindividual differences in micro-
biota composition (11). The animal-based diet increased sev-
eral species as proportions of the total sequence count that are
bile tolerant, since that diet also provided triple the fat of the
plant-based diet, whereas fiber was approximately one-third
that of the plant-based diet.
In addition to undigested carbohydrates reaching the colon,
5% of ingested fat, 8% of ingested protein, and unabsorbed
vitamins, minerals, and phytochemicals all have potential to
alter the bacteria in the large bowel. Most GI transit time is
accounted for by transit within the colon, where water and
electrolytes are absorbed, and bacteria grow on unabsorbed
nutrients, as well as sloughed epithelial cells and mucin.
However, we do not have much basic information on how
transit time affects composition or function of the colonic
microbiota, except that longer transit time is associated with
increased microbial richness (32). Up to 80 g/day of resistant
starch and 10–15 g or more of fructooligosaccharides have
been tested to show a lack of GI side effects (17). Recent
research on fermentable oligo-, di-, and monosaccharides and
polyols has shown a reduction of symptoms in some people
with irritable bowel syndrome following avoidance of those
fermentable substrates (35). There is concern that this dietary
approach greatly restricts dietary fiber intake and the healthier
foods providing that nutrient. Although there is much interest
in the health benefits of prebiotics, there are no prospective
cohort studies linking changes in the fecal microbiota with
health end points. The definition of prebiotics, proposed in the
mid-1990s, was limited to increases in only a limited number
of bacterial strains, but that was before nucleic acid-based
analyses were available. It is now appreciated that other bac-
terial changes may be induced and that those must be tied to
health benefits of the host (4), but an updated consensus
statement was published recently, suggesting such modifica-
tions (16). Whereas increased butyrate is generally accepted as
beneficial, and some intermediate markers are improved, it has
not been definitively linked to a specific hard disease end point.
Likewise, soy feeding has been studied for multiple benefits,
but recently, it has been demonstrated to increase bifidobacte-
ria and lactobacilli, as well as to alter the Bacteroidetes-
Firmicutes ratio (19). Other dietary factors that alter the gut
bacteria in humans include iron, ellagitannins, and flavanols;
far more compounds have shown such activity in animal
models. These include conjugated linoleic acid, proanthocya-
nidins, polyphenols, L-carnitine, flavanols, sphingomyelin, res-
veratrol, zinc, aspartame, saccharin, sucralose, carboxymethyl-
cellulose, and polysorbate-80. Several nondietary factors affect
transit time and laxation that in turn, might influence the
microbial composition of feces; those factors include stress,
exercise, smoking, coffee consumption, and personality. More
accurate assessment of dietary exposure is needed, along with
standardized methods, for the field to advance. All of these
factors should be recorded by investigators, since they may
reveal common influences on fecal microbiota.
Legal issues. Regarding regulatory considerations for stud-
ies of diet and the microbiome, the microbiome is a variable in
studies of diet and health that may complicate interpretation of
results. The regulatory framework relevant for microbiome
studies includes consideration of intended use, safety, and
labeling of the product. As for almost all food substances, the
Federal Food, Drug, and Cosmetic Act, as amended, and
related statutes, along with the Code of Federal Regulations
and guidance issued by federal regulatory agencies, control the
playing field. Probiotics—those species of bacteria considered
to have some health benefit—are not defined as a regulatory
product category and may be considered a food, dietary sup-
plement, or a drug, depending on the intended use of the
product. If the product is intended to treat, cure, mitigate,
or prevent disease, the U.S. Food and Drug Administration
(FDA) views it as a drug, and it is therefore subject to the
premarket approval process. Several criteria differentiate how
an ingredient is classified by the FDA (13). Mandatory food
labeling informs the consumer about the basic nature of the
food, its ingredients, the nutritional attributes, and other essen-
tial information, such as a warning about allergens. Although
certain types of claims can be made voluntarily about a
product, all labeling for which the manufacturer is responsible
must be truthful and not misleading and conform to the
E1093DIET AND THE INTESTINAL MICROBIOME
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00058.2018 • www.ajpendo.org
relevant statutes and regulations. Nutrition-related claims in-
clude structure-function claims (about maintaining health),
nutrient content claims (about nutrient profile of a product), or
health claims (disease risk-reduction claims for a food sub-
stance). Nutrient content claims and health claims require
evaluation by the agency before use in food labeling. Unau-
thorized health claims may be considered unapproved, new
drug claims if the substance purports to treat, cure, mitigate, or
prevent a disease or health-related condition. For health claims,
including qualified health claims, the FDA has provided guid-
ance on how it reviews evidence (15). Studies suitable to the
FDA are human intervention or observational studies; reviews,
meta-analyses, animal, and in vitro studies are not. Human
studies must have a control group, relevant statistical analysis,
control of key confounders, validated biomarkers, and repre-
sentation of the healthy population. The proposed, new defi-
nition of dietary fiber from the FDA includes nondigestible
soluble and insoluble carbohydrates with three or more mono-
meric units and lignin that are intrinsic and intact in plants or
isolated or synthetic, nondigestible carbohydrates with three or
more monomeric units determined by the FDA to have phys-
iological effects that are beneficial to human health. Conse-
quently, isolated or synthetic, nondigestible carbohydrates that
have not been determined to have a physiological effect that is
beneficial to human health are not considered in the total fiber
content of a product nor as the basis for a nutrient content
claim. To date, the FDA has used lowering blood pressure,
blood glucose, or cholesterol; improving laxation and bowel
function; increasing mineral absorption; or reducing energy
intake as physiological benefits to health to accept isolated or
synthetic sources of dietary fiber for inclusion on the label.
However, fermentation or effects on the microbiome have not
been considered a physiological effect, because their beneficial
effect on human health has not been established (14).
CONCLUSIONS
“If you don’t like bacteria, you’re on the wrong planet.”
–Stewart Brand
The diversity of views expressed by speakers and audience
discussants indicated that there are few clearly established best
practices for design of studies of the intestinal microbiome in
which diet is a main variable, but several best practices are
suggested (Table 1). Lack of consensus on many potential best
practices means it is incumbent on researchers to provide
enough details about food and nutrient intake for animals or
Table 1. Key points in design and reporting of diet in studies of the intestinal microbiota
Strengths Weaknesses Best Practices
General aspects of fermentable
substrates
Should define fiber or resistant starch
fully, including structure and
particle size; provide trade name.
Listing cellulose, for example, is insufficient;
there are dozens of varieties that differ in
multiple characteristics.
Provide as much detail as possible;
consider online supplemental
description.
Animal studies Mice most commonly used; can be
conventional, gnotobiotic, germ
free, or humanized.
Rodents have large cecum, are coprophagic,
and rarely get diarrhea; colony-to-colony
variation in microbiome.
Choice of species depends on
question(s) asked.
Pigs or dogs more like humans in GI
tract anatomy and microbiology.
Expense, size, specialized training needed,
and ethical issues.
Animal diets Chow-type diets inexpensive, provide
all nutrients, high amount of
fermentable substrate; open
formula chow-type diets, such as
NIH-31, do not vary over time.
Batch-to-batch variation, high polyphenol
content alters microbiota; fiber content
usually poorly characterized.
If chow-type diet, use open source
formula.
Purified diets allow complete control
of all ingredients.
The prototypical diet, AIN-93, contains no
fermentable substrate; leads to loss of
bacterial diversity over multiple
generations (39).
Purified diet is preferred for
nutritional control but requires
some fermentable substrate
(soluble fiber and/or resistant
starch).
Drinking water can be standardized
for pH, method of disinfection,
etc.
Acidified water commonly used to control
bacterial infections but leads to major
changes in microbiota (44).
Describe this in Methods section.
In vitro systems Operating conditions can be
standardized, minimal ethics
issues, easy sampling, and absence
of host factors.
Choice of “best” inoculum, nature of nutrient
supply, emulation of mucosal
environment, high water flow; lack of
donor diet history.
Describe donor health, diet,
medication; single donor better
than two, since one microbiota
outcompetes the other.
Human studies Nothing can replace controlled
feeding studies in target
population.
Poor adherence to specified diets; relatively
inaccurate recording of dietary intake and
composition; cross-sectional studies cannot
prove causality.
Provide foods from metabolic
kitchen; weigh uneaten food;
alternatively, subjects need to
record everything eaten.
Wide variation in species and
metabolites.
No agreement on what constitutes healthy
microbiota; need a biomarker of dietary
fiber intake; sampling of feces does not
accurately reflect longitudinal or horizontal
environments of the colon.
None yet
Diets can be tightly controlled. Difficult to feed diets low in polyphenols;
not clear if fiber in diet should be based
on dose, energy intake, or other factors;
little information on how transit time
affects microbiota.
Provide full detail in supplemental
Methods so studies can be
replicated or analyzed in a
systematic review.
AIN-93, American Institute of Nutrition; GI, gastrointestinal; NIH, National Institutes of Health.
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humans and even in vitro studies so that other researchers can
reproduce the work. In fact, that approach is the way graduate
students were taught to write papers decades ago. With the
trend toward shorter Methods sections or placement of them in
smaller font at the end of an article, it appears that some have
devalued the importance of that section of a research manu-
script that allows reproducibility, one of the fundamental tenets
of the scientific method. Almost all journals are now online and
offer online supplemental materials as an option; therefore, it
behooves researchers to report even more detail about diet than
would have been possible if an article were only in print, since
there are few limitations on length of online materials. For
example, a human study could include a spreadsheet with
every food purchased for a controlled feeding study, including
brand names of processed foods or the specification in as much
detail as possible for fruits, vegetables, and grains, along with
amounts consumed. This is prohibitive for observational stud-
ies that generally use food-frequency questionnaires or multi-
ple dietary recalls, but efforts are underway to replace the
older, recall-based methods with technologic approaches that
reduce or avoid bias. More human studies are also needed to
understand better how mixtures of fermentable carbohydrate
affect the microbiota and to account for marked interindividual
variation in response. We need data to determine if, for
example, the Bristol Stool Scale can be used as a simple means
of comparing dietary effects on fecal characteristics—and
presumably, the microbiota to some extent—across studies.
Basic information is not available on matters, such as whether
the total number of bacteria is important; since dietary fiber
contributes to increased fecal mass, and feces are ~50% bac-
teria, it is logical to assume that this information would be
useful in understanding dietary modulation of the gut micro-
biota.
Animal studies need to provide more detail about the type of
fiber in the diet. Even in the case of “cellulose,” there are
approximately two dozen commercially available types that
differ in particle size, water-holding capacity, and potential for
fermentation. A manufacturer may be consistent in use of one
type of cellulose for animal diets, but there is no guarantee of
that, particularly if suppliers change what is available over
time, which is common in the food industry. If a soluble
dietary fiber, such as pectin, is included in a diet, then the
percent added to the diet, its viscosity, and its degree of
methylation are important variables that potentially affect
the microbiota differentially. Among the microbial metab-
olites studied, secondary bile acids and SCFAs have re-
ceived the most attention; the latter accounts for 10% of the
energy used by humans, but it is unknown if SCFAs are used
with the same metabolic efficiency as macronutrients for the
host and to what extent other bacteria use them for meta-
bolic purposes. The pharmaceutical industry has embraced
individuality in their studies, and it is likely that the same
degree of uniqueness holds for studies of the diet and
microbiome—not to the level of everyone being unique, but
some limited number of metabotypes are likely to be iden-
tified, and the same holds for the intestinal microbiota. The
field needs to move from associations to causality, and that
will be catalyzed by the knowledge of, in as much detail as
possible, what is ingested, how it is metabolized, and what
health consequences derive from those processes.
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